This Investor Exited a $22 Million GRAIL Stake Earlier than a 50% One-Day Inventory Crash Final Month
On February 17, 2026, One Fin Capital Administration absolutely exited its place in GRAIL (NASDAQ:GRAL), promoting roughly 380,000 shares price $22.47 million.
In accordance with a Securities and Trade Fee (SEC) submitting dated February 17, 2026, One Fin Capital Administration reported the entire sale of its 380,000-share stake in GRAIL. The fund reported a quarter-end place worth lower of $22.47 million because of the sale.
-
The liquidation means GRAIL now represents 0% of the fund’s 13F AUM, down from 7.4% within the prior interval.
-
High holdings after the submitting:
-
NYSE:COF: $31.88 million (12.1% of AUM)
-
NASDAQ:NXT: $26.13 million (9.9% of AUM)
-
NYSE:RKT: $25.75 million (9.8% of AUM)
-
NASDAQ:DRVN: $24.30 million (9.2% of AUM)
-
NYSE:NSC: $23.10 million (8.8% of AUM)
-
-
As of Friday, shares of GRAIL had been priced at $46.84, up 68% this previous 12 months, effectively outperforming the S&P 500, which is as a substitute up about 15% in the identical interval.
|
Metric |
Worth |
|---|---|
|
Market Capitalization |
$1.9 billion |
|
Value (as of Friday) |
$46.84 |
|
Income (TTM) |
$147.2 million |
|
Web Earnings (TTM) |
($408.35 million) |
-
GRAIL develops early most cancers detection applied sciences, together with the Galleri screening check and diagnostic aids for most cancers, with extra work on minimal residual illness and post-diagnostic instruments.
-
The agency generates income primarily by way of gross sales of proprietary diagnostic exams and associated companies, focusing on the healthcare diagnostics market.
-
Its important prospects embrace healthcare suppliers, clinicians, and asymptomatic people over 50 looking for proactive most cancers screening options.
GRAIL is a biotechnology firm specializing in blood-based multi-cancer early detection and diagnostic options. Leveraging superior genomics and knowledge science, it goals to rework most cancers screening and analysis at scale. Its proprietary expertise and concentrate on early detection place it as a pacesetter within the quickly evolving medical diagnostics panorama.
This transfer issues as a result of it exhibits self-discipline proper earlier than a high-conviction progress story handled a surprising blow. GRAIL had been, and in some methods nonetheless is, a standout performer, using optimism round its early most cancers detection platform and powerful industrial traction, together with greater than 185,000 Galleri exams bought and income progress into the $147 million vary final 12 months. However beneath that momentum, the enterprise nonetheless carries heavy losses and execution threat tied to regulatory approval and adoption curves.
That stress got here into focus quick. A pointy, roughly 50% single-day drop following earnings highlights simply how fragile sentiment might be when expectations run forward of fundamentals.
One Fin’s broader portfolio, in the meantime, leans towards a mixture of financials, industrials, and consumer-facing names, suggesting a concentrate on firms with extra predictable money flows and clearer near-term earnings visibility. In the end, for long-term traders, this looks as if a very good reminder that self-discipline issues, and balancing threat after staggering upside may also help you sit out some steep declines.
